Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.60 |
| ▸ | ITGB2 | P05107 | 3/20 | 0.46 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.46 |
| ▸ | ITGAL | P20701 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | ALB | P02768 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.40 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5371407 | 1.00 | TTR (0.60) | TTRITGB2ICAM1ITGALCA2 | |
| SCHEMBL5367266 | 0.92 | TTR (0.62) | TTRITGB2ICAM1ITGALCA2 | |
| SCHEMBL5367263 | 0.92 | TTR (0.62) | TTRITGB2ICAM1ITGALCA2 | |
| SCHEMBL5374648 | 0.89 | TTR (0.63) | TTRITGB2ICAM1ITGALCA2 | |
| SCHEMBL5374651 | 0.89 | TTR (0.63) | TTRITGB2ICAM1ITGALCA2 | |
| SCHEMBL5371379 | 0.87 | TTR (0.61) | TTRCA2CA1ALBMEN1 | |
| SCHEMBL5371383 | 0.87 | TTR (0.61) | TTRCA2CA1ALBMEN1 | |
| SCHEMBL5379885 | 0.82 | TTR (0.66) | TTRCA2CA1ALBMEN1 | |
| SCHEMBL5379887 | 0.82 | TTR (0.66) | TTRCA2CA1ALBMEN1 | |
| SCHEMBL5371367 | 0.80 | TTR (0.63) | TTRCA2CA1ALBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265245-B2 | Compounds useful for the treatment of diseases associated with the formation of amyloid fibrils | INNOVAPROTEAN, S.L (ES) | 2007-09-04 | — | — | US | claimed |
| US-20070167378-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE FORMATION OF AMYLOID FIBRILS | INNOVAPROTEAN, S.L. (ES) | 2007-07-19 | — | — | US | claimed |
| EP-1679299-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE FORMATION OF AMYLOID FIBRILS | Innovaprotean, S.L. (ES) | 2006-07-12 | — | — | EP | claimed |
| US-7265245-B2 | Compounds useful for the treatment of diseases associated with the formation of amyloid fibrils | INNOVAPROTEAN, S.L (ES) | 2007-09-04 | — | — | US | disclosed |
| US-20070167378-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE FORMATION OF AMYLOID FIBRILS | INNOVAPROTEAN, S.L. (ES) | 2007-07-19 | — | — | US | disclosed |
| EP-1679299-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE FORMATION OF AMYLOID FIBRILS | Innovaprotean, S.L. (ES) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167378-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE FORMATION OF AMYLOID FIBRILS | APP, C1R, RTN3 | TTR 12/4885ITGB2 3894/4885ICAM1 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.